End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
41.93 CNY | -0.64% | +1.80% | -21.92% |
Mar. 28 | Beijing Tongrentang Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 06 | China Approves Tong Ren Tang Group's Clinical Trial of Heart Failure Drug | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 29.62 times its estimated earnings per share for the ongoing year.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-21.92% | 7.94B | C- | ||
+26.37% | 659B | C+ | ||
+26.47% | 557B | B | ||
-5.05% | 359B | C+ | ||
+17.01% | 322B | B- | ||
+9.12% | 297B | C+ | ||
+6.25% | 215B | B+ | ||
+5.18% | 210B | B- | ||
-5.97% | 200B | A+ | ||
-8.41% | 149B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 600085 Stock
- Ratings Beijing Tongrentang Co., Ltd